Ultragenyx Initiates New Development Program Studying Triheptanoin (UX007) for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS) NOVATO, Calif., Aug 05, 2013 (GLOBE NEWSWIRE ...
A new study of non-diabetic women with ovarian cancer reveals a potential correlation and area for further study regarding the expression of the GLUT1 glucose transporter receptor at the cancer tissue ...
The glucose transporter GLUT1, a plasma membrane protein that mediates glucose homeostasis in mammalian cells, is responsible for constitutive uptake of glucose into many tissues and organs. Many ...
Novato, CA, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
The cover for issue 57 of Oncotarget features figure 2, 'Overall survival analysis of GLUT1, PD-L1, and histologic architecture,' by Chamseddin, et al. The cover for issue 57 of Oncotarget features ...
Glut1 deficiency syndrome is a rare and disabling neurological disease still relatively unknown to the medical community. A mutation in the SLC2A1 gene in affected patients causes the glucose ...
Scientists have gleaned a key cellular mechanism of how the body adjusts glucose levels, an important process that when abnormal can promote diabetes, cancer, and rare genetic diseases. UT ...
There is now a blood test that can diagnose a rare neurometabolic condition known as Glut1 deficiency syndrome, or De Vivo disease. Glut1 deficiency syndrome is caused by a mutation in a gene called ...
Cancerous cells have an acutely increased demand for energy, leading to increased levels of human glucose transporter 1 (hGLUT1). This up-regulation suggests hGLUT1 as a target for therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback